RESEARCH PAPER
Subthreshold micropulse yellow 577 nm laser therapy of diabetic macular oedema in rural and urban patients of south-eastern Poland
| 1 | Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin |
| 2 | Department of Vitreoretinal Surgery, Medical University, Lublin |
CORRESPONDING AUTHOR
Małgorzata Latalska
Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin
Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin
Ann Agric Environ Med. 2017;24(1):96–99
KEYWORDS
ABSTRACT
Objectiv:
To evaluate the efficacy of subthreshold micropulse yellow (577 nm) laser photocoagulation in diffuse macular edema (DME) in rural and urban patients of south-eastern Poland.
Material and Methods:
Seventy-five eyes of 75 patients with diffuse DME were treated with subthreshold micropulse yellow laser photocoagulation with a 5% duty cycle at an energy level. The laser exposure time was 20 ms and the spot diameter was 100 μm. Best corrected visual acuity (BCVA), reading vision (Snellen) and optical coherence tomography-determined central retinal thickness (CRT) were estimated before and 2, 4 and 6 months after laser treatment. There were no statistically important differences in: the advancement of DME, HbA1c (glycated hemoglobin) level, duration of diabetes mellitus (DM), the degree of vision damage between rural and urban patients.
Results:
The follow-up was 6 months later. The baseline BCVA was 0.20 and remained stable- 0.3 after 6 months. The Snellen at baseline was 1.0 and improved to 0.5 finally (p=0.0004). The CRT at baseline was 500 μm and changed to 346 μm (p=0.00000) at the final follow-up. Finally, no retinal damage was observed.
Conclusions:
Place of residence had no statistically significant effect on the demographics data, baseline visual acuity, reading visual acuity and central retinal thickness. Subthreshold micropulse yellow laser showed a highly significant efficiency in the treatment of DME. The effects of the treatment were more significant in rural patients than in urban ones.
To evaluate the efficacy of subthreshold micropulse yellow (577 nm) laser photocoagulation in diffuse macular edema (DME) in rural and urban patients of south-eastern Poland.
Material and Methods:
Seventy-five eyes of 75 patients with diffuse DME were treated with subthreshold micropulse yellow laser photocoagulation with a 5% duty cycle at an energy level. The laser exposure time was 20 ms and the spot diameter was 100 μm. Best corrected visual acuity (BCVA), reading vision (Snellen) and optical coherence tomography-determined central retinal thickness (CRT) were estimated before and 2, 4 and 6 months after laser treatment. There were no statistically important differences in: the advancement of DME, HbA1c (glycated hemoglobin) level, duration of diabetes mellitus (DM), the degree of vision damage between rural and urban patients.
Results:
The follow-up was 6 months later. The baseline BCVA was 0.20 and remained stable- 0.3 after 6 months. The Snellen at baseline was 1.0 and improved to 0.5 finally (p=0.0004). The CRT at baseline was 500 μm and changed to 346 μm (p=0.00000) at the final follow-up. Finally, no retinal damage was observed.
Conclusions:
Place of residence had no statistically significant effect on the demographics data, baseline visual acuity, reading visual acuity and central retinal thickness. Subthreshold micropulse yellow laser showed a highly significant efficiency in the treatment of DME. The effects of the treatment were more significant in rural patients than in urban ones.
REFERENCES (26)
1.
Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003; 290: 2057–2060.
2.
Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003; 5: 12–21.
3.
Tong L, Vernon SA, Kiel W, Sung V, Orr GM. Association of macular involvement with proliferative retinopathy in type 2 diabetes. Diabet Med. 2001; 18: 388–394.
4.
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009; 116(3): 497–503.
5.
Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol. 2008; 2: 919–930.
6.
No authors listed. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985; 103: 1796–1806.
7.
Simó R, Hernández C. Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care 2009; 32(8): 1556–1562.
8.
Titchenell PM, Antonetti DA. Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy. Diabetes. 2013; 62(6): 1808–1815.
9.
Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007; 114: 1860–1867.
10.
Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116(11): 2175–2181.
11.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615–625.
12.
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33(11): 2399–2405.
13.
Do DV, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br J Ophthalmol. 2009; 93(2): 144–149.
14.
Ho AC, Scott IU, KimSJ, Brown GC, Brown MM, Ip MS, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology 2012; 119 (10): 2179–2188.
15.
Cheung N, Wong IY, Wong TY. Ocular Anti-VEGF Therapy for Diabetic Retinopathy: Overview of Clinical Efficacy and Evolving Applications. Diabetes Care. 2014; 37(4): 900–905.
16.
Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? Semin Ophthalmol. 2004: 19(1–2); 62–68.
17.
Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010; 30(6): 908–916.
18.
Lavinsky D, Cardillo JA, Melo LA Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011: 52; 4314–4323.
19.
Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014, 4:27.
20.
Binz N, Graham CE, Simpson K, Lai YK, Shen WY, Lai CM, et al. Long-term Effect of Therapeutic Laser Photocoagulation on Gene Expression in the Eye. FASEB J. 2006; 20(2): 383–385.
21.
Ogata N, Tombran-Tink J, Jo N, Mrazek D, Matsumura M. Upregulation of Pigment Epithelium – Derived Factor after laser photocoagulation. Am J Ophthalmol. 2001; 132(3): 427–429.
22.
Yu AK, Merril KD, Truong SN, Forward KM, Morse LS, Telander DG. The Comparative Histologic Effects of Subthreshold 532-and 810-Nm Diode Micropulse Laser on the Retina. Invest Ophthalmol Vis Sci. 2013 1; 54(3): 2216–24.
23.
Kwon YH, Lee DK, Kwon OW. The Short-term Efficacy of Subthreshold Micropulse Yellow (577-nm) Laser Photocoagulation for Diabetic Macular Edema. Korean J Ophthalmol. 2014; 28(5): 379–385.
24.
Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol. 1999; 14: 200–209.
25.
GŁÓWNY URZĄD STATYSTYCZNY: Sytuacja demograficzna osób starszych i konsekwencje starzenia się ludności Polski w świetle prognozy na lata 2014–2050. http://www.stat.gov.pl (access: 2016.03.18).
26.
Duda G, Wichura-Demska A. Wpływ wybranych czynników socjo-demograficznych na poziom wiedzy osób zdrowych na temat cukrzycy. Bromat. Chem. Toksykol. 2009; 42(3): 995–999.
Improvement of visual identification of the journal - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher Education allocated to the activities of disseminating science.
Generation of the DOI (Digital Object Identifier) - task financed under the agreement No. 618/P-DUN/2019 by the Minister of Science and Higher
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.